PTPRC and prostate carcinoma: We investigated CD45 expression in circulating tumor cell (CTC)-like populations to define the cellular identity of CD45+ subsets through immunostaining, PBMC clustering, and transcriptomic profiling of metastatic prostate cancer samples.